فهرست مطالب mahzad motallebi

Cancer is a malignant disease of increasing concern on account of its high heterogeneity, high mortality and morbidity rates, as well as absence of targeted and effective therapeutic regimes. The recent introduction of biomimetic and nature-inspired principles in the development of nanosystems has significantly impacted cancer therapies and diagnosis. Biomembrane-surface engineered nanosystems are bioinspired nanoconstructions equipped with cell-mimicking features to improve in vivo interactions with surrounding biological environments and cells. These next-generation nanosized delivery systems can enhance therapeutic efficacy and safety of conventional cancer therapies by providing highly specific, targeted, and safer nanomedicines. Herein, we have discussed the unique features of cell membrane-coated biomimetic nanodevices (including superior biocompatibility, immune evasion and tissue-homing features) that allow for promising osteosarcoma-targeted diagnosis, therapy, and theranostics. We also summarized the recent advances on cell membrane- and hybrid cell membrane-coated nanosystems for both primary bone cancer and metastatic scenarios, especially prostate cancer-derived bone metastases. Future perspectives and challenges towards successful clinical translation are also highlighted.

Drug nanocarriers have been used extensively in cancer therapy due to their features like the ability to targeting drug transmission, increasing drug solubility, and reducing the drug cytotoxic effects on healthy tissues. The purpose of this study was to investigate the effects of Tamoxifen nanocapsules on the expression of Bax and Bak genes in MCF-7 cell lines.

In this study, the nanocapsule structure was confirmed by FTIR spectroscopy and the effects of Tamoxifen nanocapsules on cell bioactivity were evaluated by MTT assay at concentrations of 10, 50, 100, and 200 µg/mL after 48 hours. Real-time PCR was used to analyze the expression of Bax and Bak genes and data were analyzed using SPSS (23.0) software.

According to the MTT assay, higher concentrations of Tamoxifen nanocapsules decreased cell bioactivity in a dose-dependent manner and the highest toxicity of nanocapsules was at the concentration of 200 µg/mL. The expression level of Bax and Bak genes in MCF-7 treated cells after 48 hours indicated the induction of apoptosis in cells. The results revealed a 1.8-fold increase in cytotoxicity of Tamoxifen nanocapsules compared to free Tamoxifen.

The apoptosis induction as a result of increased expression of Bax and Bak genes and enhanced cytotoxicity, makes Tamoxifen nanocapsules a promising treatment for breast cancer therapy compared to free Tamoxifen.